STOCKS TELEGRAPH

Category: Featured

  • What Motivated Tonix (TNXP) Stock To Climb 5% This Morning?

    At last check in current trading, shares of Tonix Pharmaceuticals Holding Corp. (TNXP) were up 5.22% at $0.198. Tonix (TNXP) stock closed the last session at $0.19. Shares of the company were fluctuating between $0.1822 and $0.1921. The number of shares exchanged was 2.34 million, less than the company’s 50-day daily volume of 15.98 million and lower than its Year to date volume of 17.04 million. TNXP stock is surging after entering into an agreement.

    Which understanding does Tonix has gone into?

    Tonix (TNXP) is a clinical-stage biopharmaceutical organization zeroed in on finding, permitting, procuring, and creating therapeutics and diagnostics to treat and forestall human infection and reduce languishing. TNXP’s portfolio is made out of irresistible sickness, focal sensory system (CNS) and immunology item up-and-comers.

    Tonix (TNXP) on Monday declared that it has gone into a supported examination concurrence with Inserm Transfert, the private auxiliary of Inserm, in the interest of Inserm (the French National Institute of Health and Medical Research) and Aix-Marseille Université.

    • The exploration arrangement is to concentrate on oxytocin in the hereditarily designed mouse model of Prader-Willi condition, an uncommon hereditary problem that causes unmistakable, however, related neurotic dietary issues in grown-ups and infants.
    • In grown-ups, Prader-Willi causes hyperphagia, or neurotic over-eating, which prompts weight and different intricacies related to huge mortality.
    • In infants, Prader-Willi causes a lack in nursing, which has been demonstrated to be standardized by oxytocin treatment.
    • The proposed research, coordinated by Professor Françoise Muscatelli at the Institut de Neurobiologie de la Méditerranée (INMED-Inserm UMR1249/Aix-Marseille Université), will include in vitro and in vivo investigations.
    • Those reviews are intended to describe the component by which oxytocin standardizes the nursing and development of taking care of conduct during early stages in mice that have been hereditarily adjusted to restate part of the hereditary modifications hidden Prader-Willi in people.
    • The aftereffects of this work are relied upon to build the comprehension of the instrument by which oxytocin directs taking care of conduct in a mouse model of Prader-Willi.

    What TNXP is up to?

    Tonix (TNXP) is creating TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi Syndrome in grown-ups and youths. A related intranasal potentiated oxytocin item applicant, TNX-1900, is likewise being worked on at TNXP for the therapy of persistent headache and is relied upon to enter a Phase 2 clinical preliminary for the avoidance of headache cerebral pain in constant migraineurs in the last part of 2022.

  • What Is Driving The Skillful Craftsman (EDTK) Stock Higher In Early Trades?

    Skillful Craftsman Education Technology Limited (EDTK) is rising on the charts today, up 6.92% to trade at $1.78 at last check in current market trading. On Tuesday, shares in Skillful Craftsman (EDTK) fell -5.92% to close the day at $1.59. The volume of shares traded was 0.0, which is lower than the average volume over the last three months of 411.89K. During the trading session, the stock oscillated between $1.55 and $1.76. The company had an earnings per share ratio of -0.08.

    Skillful Craftsman (EDTK) stock has gained 12.77% of its value in the previous five sessions and moved 15.22% over the past one month, but has gained 68.22% on a year-to-date basis. The stock’s 50-day moving average of $1.2260 is above the 200-day moving average of $1.5369. Moreover, the stock is currently trading at an RSI of 63.49. EDTK stock is rising after a collaboration agreement.

    What understanding does EDTK has made?

    Skillful Craftsman (EDTK) is an instruction innovation organization that gives intuitive internet-based professional preparation and programmatic experience test instructional classes. EDTK started tasks in Wuxi, China in 2013 and is a vital ally for China schooling change and advancement for work business.

    Skillful Craftsman (EDTK) reported that the Company went into an essential participation understanding (the “Arrangement”) with Jiangsu Hibao Tech Software Co., Ltd. (“Hibao”), a brilliant plant innovation supplier, to foster its Meta-Factory, a shrewd specialized ability preparing Metaverse stage.

    According to the Agreement, the two players consent to foster Meta-Factory for giving professional schools and assembling industry clients with team-oriented cooperative and multi-scene reproduction preparing bases, which are intended to assist them with successfully taking care of the quick advancing work market of assembling manufacturing plants.

    Hibao consents to give essential information of assembling industry and EDTK consents to be answerable for building the vitual reality (“VR”) brilliant activity stage and developing professional preparation bases.

    Building a Metaverse stage is critical for professional understudies to have a vivid ability to prepare experience that meets the pattern of the business.

    Adhering to the rule of the Chinese government and its arrangement to advance professional schooling, EDTK is focused on serving understudies and professional universities with its advances and updated ability preparing stage and assisting them with meeting the fast improvement pattern of the cutting edge brilliant plants.

    What EDTK will accomplish from this coordinated effort?

    The advancement of Meta-Factory is a critical achievement for Skillful Craftsman (EDTK) to prepare to accomplish a drawn-out objective of giving great stages of preparation to understudies. For fostering its Meta-Factory, EDTK teams up with Hibao to use particular benefits and have an exclusive requirement for what Meta-Factory can bring to the professional training industry.

  • Bright Health Group, Inc. (BHG) Stock Nose-dived Today Following Financials Release.

    Bright Health Group, Inc. (BHG) is the leading and foremost tech-enabled care platform built for healthcare’s customer retail market. Its differentiated methodology aligns delivery of care with the care financing to approach improved results, lesser costs, and improve the client’s experience.

    The price of BHG stock during regular trading on March 1, 2022, was $3.12 with a decline of 6.02%. At last check in the current market on March 2, 2022, the stock was further down by 23.48%.

    BHG: Key Financials

    On March 2, 2022, BHG released its unaudited financial statement of Q4 2021 ended December 31, 2021. Some of the prominent features are discussed below.

    Revenue

    Total revenue during Q4 2021 was recorded to be $0.96 billion versus $0.35 billion in the same period of 2020. The company observed a $0.6 billion gain in its revenue over the year. The company missed the revenue estimates of $1.08 billion.

    EPS

    Basic and diluted net loss per share in Q4 2021 was $0.81 billion or $1.29 against $0.16 billion or $1.20 in the same period of the previous year. The company observed a significant increase in its net loss over the year. Also, the company missed the estimates of the analysts of -$0.49.

    BHG: Events and Happenings

    On January 10, 2022, BHG reported its 2022 Bright HealthCare AEP/OEP Membership guidance across its Commercial and Medicare business lines. The augmented membership estimate reflects better retention and development in central markets during open enrollment. On January 5, 2022, BHG updated on its Executive management’s presentation at the 40th Annual J.P. Morgan Healthcare Conference held on January 11, 2022.

    On January 3, 2022, BHG announced the completion of the offering of 750,000 shares of its convertible preferred stock. The shares were sold to Cigna Corporation subsidiaries and New Enterprise Associates affiliates. The gross proceeds from the offering were approximately $750 million.

    Conclusion

    BHG stock is on a declining verge for the past year as its stock position was 81% down the period. This downfall is the result of the pandemic as most other companies are facing. The recent current market stock decline was observed after the company reported its financial statement and missed the expectations of the company and analysts in revenue and EPS.

  • What Happened To Make Guardforce AI (GFAI) Stock Drop Today?

    Shares of the integrated security solutions provider, Guardforce AI Co. Limited (GFAI) have dropped -5.08% at $0.56 in Wednesday’s current market session. Guardforce AI (GFAI) stock added 0.02% to finish the last trading session at $0.59. The stock recorded a trading volume of 22.13 million shares, which is above the average daily trading volume published for the last 50 days of 4.12 million shares.

    The shares of Guardforce AI (GFAI) have advanced 36.20% in the last five days; however, they have lost -19.54% over the last month. The stock price has shed -59.31% over the last three months and has lost -45.37 percent so far this year. GFAI stock is falling even after a strategic collaboration.

    Which collaboration does Guardforce AI has gone into?

    Guardforce AI (GFAI) is a main coordinated security arrangements supplier that is trusted to safeguard and ship the high-esteem resources of public and private area associations. Creating and presenting inventive innovations that improve wellbeing and insurance, GFAI assists clients with taking on new advancements and working securely as the Asia Pacific business scene advances.

    Guardforce AI (GFAI) declared that the Company has laid out an essential association with SBC Global Holdings Inc. (“SBC”).

    • GFAI went into the essential association in lieu of the recently proposed procurement.
    • GFAI and SBC have commonly consented to layout the essential organization to empower Guardforce AI a swifter passage into the ideal U.S. markets with its automated and innovation arrangements.
    • As a feature of the association GFAI will lay out a completely claimed U.S. auxiliary and will submit extra assets to foster the business to satisfy developing needs while working intimately with SBC to speed up by and large market entrance.
    • As a component of the arrangement, SBC will allude all clients to GFAI on a selective premise.
    • The association will permit clients in the United States to approach independent mechanical technology arrangements that will bring about functional efficiencies and further develop ecological security principles.
    • As per Gartner, U.S. Web of Things (“IOT”) Robots Revenues and Communications spending is relied upon to reach roughly $6.5 billion with an established base of around 1.7 million units by 2028.
    • With sizeable mechanical development habitats arising worldwide, the chance for associations keeps on growing quickly.

    How the organization will help GFAI?

    Counting the SBC group as a component of the organization’s developing organization of global associations, Guardforce AI (GFAI) will be utilizing the organization to incorporate vital U.S. markets into its portfolio. The new organization is important for GFAI’s obligation to work intimately with the right organizations all over the planet fully intent on extending the scope of its administrations and arrangements.

  • Purple Innovation, Inc. (PRPL) declined in the current market; here is why?

    Purple Innovation, Inc. (PRPL) declined in the current market after announcing its fourth quarter and fiscal 2021 results. PRPL values at $5.56, losing more than 2.88% compared to yesterday’s closing price. The stock closed at $5.73 at the end of the last trading session. The stock volume traded in the previous trading session was around 1.98 million shares. The current market cap of the company is about $383.50 million.

    PRPL: Q4 and Fiscal 2021 Key Financials

    • Purple Innovation, Inc.’s revenue in Q4 2021 was $186.4 million. It is an increase of more than 7.2% compared to the revenue of $173.9 million in Q4 2020.
    • Fiscal 2021 revenue was $726.2 million, 12% more than the revenue of $648.5 million in fiscal 2020.
    • The company’s net loss in Q4 2021 was around $21.8 million, less than compared to the net loss of $73.5 million in Q4 2020.
    • PRPL net income in fiscal 2021 was around $3.9 million, and profitability improved significantly compared to the net loss of $229.8 million in fiscal 2020.
    • The Q4 2021 adjusted loss per share was $0.35, compared to a net loss of $0.07 in Q4 2020.
    • For fiscal 2021, the adjusted loss per share was $0.19, compared to $0.79 in fiscal 2020.

    PRPL New CEO Appointment

    Robert DeMartini has been named the new Chief Executive Officer of the company, effective upon completing an updated and restated employment agreement.

    PRPL 2022 Outlook

    The Company presently estimates full-year revenue of $790 to $830 million in 2022, increasing 8% to 14% over 2021. In 2022, adjusted EBITDA is estimated to be between $26 and $33 million, compared to $11.0 million in 2021. The Company presently forecasts revenue of $125-$135 million and adjusted EBITDA of $(26)-$(20) million for the first quarter of 2022.

    Conclusion

    Purple Innovation, Inc. (PRPL) declined following the announcement of the Q4 and fiscal 2021, along with the appointment of a new CEO. In December 2021, DeMartini was named as Interim Chief Executive Officer.

  • What Drove The Adagene (ADAG) Stock Up 11% During Pre-Hours Trading?

    At last check in pre-market trading, shares of Adagene Inc. (ADAG) were up 11.27% at $6.12. Adagene (ADAG) stock closed the last session at $5.50, increasing 1.10% or $0.06. Shares of the company fluctuated between $5.33 and $5.74 throughout the day. The number of shares exchanged was 3744.0, less than the company’s 50-day daily volume of 14474.0 and lower than its Year to date volume of 12873.0.

    In the past 12 months, Adagene stock has retreated -77.98%, and in the last one week, the stock has moved down -17.91%. For the last six months, the stock has lost a total of -67.59%, and over the last three months, the stock has decreased by -35.29%. The stock has returned -31.83% so far this year. ADAG stock is rising following a collaboration deal.

    What cooperation does Adagene went into?

    Adagene is a stage-driven, clinical-stage biopharmaceutical organization focused on changing the revelation and advancement of novel neutralizer-based disease immunotherapies. ADAG consolidates computational science and man-made brainpower to plan novel antibodies that address neglected patient necessities.

    Controlled by its restrictive Dynamic Precision Library (DPL) stage, made out of NEObody, SAFEbody, and POWERbody innovations, ADAG’s profoundly separated pipeline highlights novel immunotherapy programs. ADAG has fashioned key joint efforts with respectable worldwide accomplices that influence its innovation in various methodologies at the vanguard of science.

    Adagene (ADAG) today declared a cooperation and selective permit concurrence with Sanofi to create covered monoclonal and bispecific antibodies for improvement and commercialization by Sanofi.

    • Under the conditions of the arrangement, Adagene will be liable for beginning phase research exercises to foster veiled adaptations of Sanofi competitor antibodies, utilizing Adagene’s SAFEbody innovation.
    • Sanofi will be exclusively answerable for later-stage exploration and all clinical, item advancement, and commercialization exercises.
    • Sanofi will make a forthright installment of $17.5 million to ADAG and can propel two beginning Sanofi immune response competitors in the coordinated effort, trailed by a possibility for two extra up-and-comers.
    • Furthermore, ADAG will be qualified to get all out expected improvement, administrative, and business achievement installments of up to $2.5 billion for progression of the competitors, which will be solely evolved and popularized by Sanofi.
    • ADAG is qualified to likewise get layered eminences on worldwide net deals of supported joint effort items.

    ADAG’s further joint efforts

    As well as continuous coordinated efforts, Adagene (ADAG) is building a profound, wide, and separated pipeline of extraordinary neutralizer-based therapeutics. An aggregate of five-item applicants are in clinical turn of events, made utilizing ADAG’s AI-fueled counteracting agent innovation stage. These incorporate three entirely claimed clinical resources in stage 1b/2 advancement by ADAG, and two item competitors out-licensed in Greater China. Furthermore, Adagene has five immunizer-based applicants in IND-empowering studies and north of 50 additional across various phases of revelation.

  • What Drove Sasol (SSL) Stock Up 10% In Pre-Market Session?

    What Drove Sasol (SSL) Stock Up 10% In Pre-Market Session?

    Shares of the South African energy and chemical company Sasol Limited (SSL) have advanced 10.30% at $25.70 in pre-market trading hours on the last check Wednesday. The stock of Sasol (SSL) gained 1.44% to complete the last trading session at $23.30. The price range of the company’s shares was between $23.09 and $24.12. It traded 0.46 million shares, which was above its daily average of 0.42 million shares over 100 days.

    Sasol (SSL) shares have gained by 6.64% in the last five days, while they have added 8.27% in the last month. Further, it is currently trading at a price-to-earnings ratio of 24.05 and a price-to-book ratio of 1.35. Additionally, the price to cash flow ratio stood at 9.77. SSL stock is on the rise after news emerged that it selling some of its assets.

    Which assets Sasol has been selling?

    Sasol (SSL) is a producer of excellent compound items with creation offices in Brunsbüttel and Marl and central command in Hamburg. Around 1,700 workers and very nearly 100 disciples produce imaginative, practical items and foster answers for the handling business.

    SSL offers a wide scope of items, including substances for the creation of cleansers and cleaning specialists, paints and coatings, beauty care products, and drug items. Likewise, specialties, for example, high-immaculateness and super high-virtue aluminas are utilized, for instance, as impetus transporters in exhaust systems for the car business, modern applications, and superior execution abrasives.

    Sasol (SSL) today reported that it offers its German auxiliary Sasol Wax GmbH to AWAX s.p.a., a worldwide gathering that had practical experience in creating, delivering, and conveying wax items.

    • SSL with two creation offices in Hamburg, Germany, one in the UK and one in Austria will work under the name Hywax GmbH successful 1 March 2022.
    • The deal happens as a component of a bundle of measures with which SSL repositions itself.
    • The portfolio is being smoothed out by focusing on center resources.
    • Barred from the deal is the South African Fischer-Tropsch hard wax business.
    • The exchange likewise remembers the part for Europe that is overseen by Sasol Wax GmbH.
    • This business will stay with SSL.
    • Establishing and offering to an essential financial backer for the organization’s European wax business will permit SSL to make one more significant key stride towards zeroing in on its center resources.

    How AWAX will use SSL resources?

    Sasol Wax GmbH at Sasol (SSL) has the most progressive wax hydrogenation facility on the planet. With this procurement from SSL, AWAX will become ready to additionally extend its wax item portfolio and reinforce its innovative administration in the wax market.

  • Ardelyx, Inc. (ARDX) Stock Rebounds Premarket Following a SEC Filing

    Ardelyx, Inc. (ARDX) is a leading biotechnology company engaged in the discovery, development, and marketing of medicines to improve patients with cardiorenal and kidney diseases. The pipeline candidate of the company is tenapanor in Phase 3 trials, which is used to control serum phosphorus in dialysis patients. Another product candidate is RDX013 for the treatment of hyperkalemia and metabolic acidosis.

    The price of ARDX stock during regular trading on March 1, 2022, was $0.72 with a decline of 5.45%. At last check in the premarket on March 2, 2022, the stock rebounded by 10.58%.

    ARDX: Events and Happenings

    On March 1, 2022, ARDX updated the recent filing with the Securities and Exchange Commission regarding the securities offered to employees according to employee benefit plans.

    ARDX: Key Financials

    On February 28, 2022, ARDX released its financial results for the fourth quarter of 2021 ended December 31, 2021. Some of the notable features are mentioned below.

    Revenue

    Total revenues during Q4 2021 were recorded to be $1.02 million versus $1.8 million in the same quarter of 2020. The company observed a $0.78 million decline in its revenue year-over-year. The company topped the revenue estimates by $8,600.

    EPS

    Basic and diluted net loss during the fourth quarter of 2021 was $36.2 million or $0.31 per share versus $28.8 million or $0.32 per share in the same year-ago period. The company observed an increase in its net loss over the year. Also, the company missed the estimates of the analysts by -$0.05.

    On February 24, 2022, ARDX reported its entry into a debt financing contract with SLR Capital Partners investment affiliates. On February 4, 2022, ARDX announced the grant of four employees’ options by its BoDs for the acquisition of up to 35,547 shares of its common stock. The company also granted a sum of 25,750 Restricted Stock Units to its five employees. Every stock option had an exercise price of $0.84 per share.

    On November 30, 2021, ARDX informed in the press release about its plan to unveil IBSRELA in Q2 2022. It is the certified treatment of the company for irritable bowel syndrome with constipation. On November 11, 2021, ARDX reported its Executive management’s participation at the Virtual Jefferies London Healthcare Conference held on November 16 – 19, 2021.

    Conclusion

    ARDX stock downplayed by 89% in 2021 as the reaction of the pandemic on the economy. The company’s stock gained momentum in the current premarket as it reported the recent SEC filing of securities offered to its employees. For the first fiscal quarter of 2022, the analysts expect $2 million in revenue and -$0.22 EPS.

  • Color Star Technology Co., Ltd. (CSCW) Stock Declined Premarket After Partnership Announcement.

    Color Star Technology Co. Ltd., (CSCW) is a company primarily focused on entertainment and education. It is the provider of digital entertainment and music education services. The company’s digital education is provided by its Color World music and entertainment educational system.

    The price of CSCW stock during regular trading on March 1, 2022, was $0.23 with a minute decline of 2.62%. At last check in the premarket on March 2, 2022, the stock declined by 1.30%.

    CSCW: Events and Happenings

    On March 1, 2022, CSCW reported that one of the luxury women’s watches French brand ‘Galtiscopio Gatti’ had formally entered the company’s metaverse portfolio. The company will support the online marketing of the brand along with helping it grab the new market prospects presented by the metaverse. On February 25, 2022, CSCW updated on its entry into a sponsorship contract with Villareal CF, which is the European soccer powerhouse. Both the companies together embarked hand in hand on a football ride.

    On February 24, 2022, CSCW announced the completion of its registered direct offering for the acquisition and sale of 25,000,000 ordinary shares and warrants (making a unit). The acquisition price was $0.4 per unit. The net proceeds from the sale of the securities were around $10.0 million. The warrants are exercisable at a per-share price of $0.4. The gross proceeds from the offering will be utilized for general corporate purposes.

    On February 23, 2022, CSCW informed the press that ‘Unbounded Human’, an Asian trendy clothing brand had entered CSCW. It is the initial Asian high-end clothing brand to land on the company’s platform. On February 18, 2022, CSCW updated on its co-operation with Jilin Great World Aviation Service Co., Ltd. for the introduction of enterprises to the company’s APP. The main goal of the company is to set up a virtual ticketing hall along with carrying virtual collaboration in business hotels and tourism.

    On February 16, 2022, CSCW reported that its entertainment metaverse software is available on Android App Store for download.

    CSCW: Key Financials

    On November 2, 2021, CSCW released its full fiscal year financial outcomes for the year ended June 30, 2021. Some of the important features are mentioned below.

    Revenue

    Revenue during the full year of 2021 was observed to be $6.8 million versus no revenue in the fiscal year 2020. The company observed a 100% increase in its revenue year-over-year.

    EPS

    Basic and diluted net loss in fiscal 2021 was $8.23 million or $0.12 per share in comparison to $11.6 million or $0.99 per share in the same period of 2020. The company recorded an incline in its EPS over the year.

    Conclusion

    CSCW stock down-performed by 78% in the last six months as the companies were facing extreme recession in the pandemic. The current premarket fall in the stock price is the outcome of the announcement of the entry of a French luxury brand into the company’s portfolio.

  • VEON Ltd. (VEON) stock gained in the Pre-market; here is why?

    VEON Ltd. (VEON) gained in the pre-market after announcing the resignation of Mr. Fridman, the director of BoD. VEON values at $0.42, gaining more than 10.53% compared to yesterday’s closing price. The stock closed at $0.38 at the end of the last trading session. The stock volume traded in the previous trading session was around 10.82 million shares. The current market cap of the company is about $1.11 billion.

    VEON: Resignation of the Director of Board of Director

    The company announced a recent change in the managerial position today. The company announced in a press release that Mr. Fridman has decided to resign from his position as a director of the VEON Board of Directors, effective February 28, 2022. The news is followed by the recent announcement of its fourth-quarter results, which was an incredible quarter.

    VEON: Q4 Key Highlights

    The company reported revenue of $2.05 billion compared to the revenue of $1.82 billion. The increase is around 11.1% YoY.

    The company reported a net income of $801 million in Q4 compared to the net loss of $315 million in the same period last year. The positive change in profitability in the trailing twelve months is phenomenal.

    The announcement recently showed its intention to shift its parent company group to the U.K. The company also announced its Russian Beeline mobile operator collaboration with Yandex.

    VTB Bank told the firm on February 17, 2022, that its subsidiary had entered into a seven-year RUB 30 billion (up to $400 million) loan with the bank. VEON Holdings B.V is guaranteeing the loan.

    Conclusion

    VEON Ltd. (VEON) is amongst Ukraine’s most extensive mobile networks. The current emergency in Ukraine has caused businesses to halt. VEON has been severely affected by the Russian invasion like other companies in Ukraine. Its stock was already down due to the hit by the pandemic. The current uncertain situation has escalated the decline in the stock, despite reporting a robust financial statement for the fourth quarter of fiscal 2021.